A major shift in the 2026 global industry is the record-breaking transition away from "Generic Cytoreduction." While hydroxyurea has been the workhorse for decades, the Polycythemia Vera Market is seeing a mass migration toward long-acting interferons that offer molecular remission. This year, data from the THRIVE study confirmed that patients on biologics have a 96% thrombosis-free survival...
Deutsch 
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt